$300 Hep C Cure Just as Good as $84,000 Alternative

Non-profit organization DNDi has developed a low-cost hepatitis C treatment that stands to benefit 71 million people.

Protesters / Image: Josep Lago
Protesters / Image: Josep Lago

A recent article from The Guardian had good news for the 71 million people affected by hepatitis C, the blood-borne viral infection that causes 400,000 deaths a year. The non-profit Drugs for Neglected Diseases initiative (DNDi) has teamed up with Egypt’s Pharco Pharmaceuticals to create a two-pill treatment for the disease that’s expected to cost just $300.

The drugs, ravidasvir and sofosbuvir, are a welcome alternative to versions from Gilead and AbbVie, which can cost up to $84,000. The DNDi reported that the new treatment cured 97% of patients within 12 weeks.

List: Digitalization Companies From PACK EXPO
Looking for CPG-focused digital transformation solutions? Download our editor-curated list from PACK EXPO featuring top companies offering warehouse management, ERP, digital twin, and MES software with supply chain visibility and analytics capabilities—all tailored specifically for CPG operations.
Download Now
List: Digitalization Companies From PACK EXPO
Have You Heard About our Podcasts?
Through the Line podcasts explore innovations and information across the packaging and processing landscape. Join us for the latest insights, trends, and strategies shaping packaging and processing today.
Listen Today
Have You Heard About our Podcasts?